Although allogeneic hematopoietic cell transplantation (HCT) from a related donor is effective therapy for younger patients with AML, it remains unknown how the availability of a related donor affects the outcome when unrelated HCT is a treatment option for patients without a related donor. To address this issue, we retrospectively analyzed 605 cytogenetically non-favorable AML patients younger than 50 years for whom a related donor search was performed during first CR (CR1). The 4-year OS was 62% in 253 patients with a related donor and 59% in 352 patients without a related donor (P ¼ 0.534). Allogeneic HCT was performed during CR1 in 62% and 41% of patients with and without a related donor, respectively. Among patients transplanted in CR1, the cumulative incidence of non-relapse mortality was significantly higher in patients without a related donor (P ¼ 0.022), but there was no difference in posttransplant OS between the groups (P ¼ 0.262). These findings show the usefulness of unrelated HCT in younger patients with cytogenetically non-favorable AML who do not have a related donor. The extensive use of unrelated HCT for such patients may minimize the potential disadvantage of lacking a related donor.
INTRODUCTION
Owing to the strong anti-leukemic effect of pre-transplant conditioning therapy in combination with the post-transplant GVL effect, allogeneic hematopoietic cell transplantation (HCT) is currently the most powerful method for preventing relapse of AML. 1 However, the efficacy of allogeneic HCT is compromised by a high risk of treatment-related mortality, which raises the question of whether allogeneic HCT is truly beneficial for AML patients who are in their first CR (CR1). Historically, this question has been investigated in prospective studies that used biologic assignment according to donor availability, in which patients with an HLA-identical sibling donor were assigned to allogeneic HCT, whereas those without an HLA-identical sibling donor were assigned to chemotherapy and/or autologous HCT. [2] [3] [4] [5] [6] [7] [8] If we combine the results from those studies, we find that allogeneic HCT during CR1 confers a survival advantage in patients with cytogenetically intermediate and unfavorable risk. [8] [9] [10] However, such 'donor vs no-donor' studies do not provide an accurate picture of clinical practice, because an HLA-identical sibling is not the only donor source and a substantial proportion of patients without a related donor receive allogeneic HCT from an unrelated donor.
To examine how related donor availability affects the outcome of AML in a situation where unrelated HCT is a treatment option for patients without a related donor, we retrospectively analyzed cytogenetically non-favorable AML patients under the age of 50 years for whom a related donor search was conducted during CR1. The main objectives of this study were to assess the difference in survival according to related donor availability in terms of (1) overall outcome, (2) outcome after allogeneic HCT in CR1 (that is, comparison between related and unrelated HCT) and (3) outcome after first relapse following chemotherapy. We also looked at how unrelated HCT was incorporated into the treatment strategy in our patient cohort.
PATIENTS AND METHODS Patients
Adults with AML who had achieved CR1 were retrospectively registered in a Japanese nationwide AML database, which formed the basis of this study. Seventy institutions contributed patients to the database. Patients were eligible if they were younger than 50 years, were diagnosed with AML from 1999 to 2006 according to the World Health Organization (WHO) classification, 11 had achieved CR with one or two courses of chemotherapy, and had a related donor search performed during CR1. We excluded patients with acute promyelocytic leukemia and core-binding factor AML, as well as those whose pre-treatment cytogenetic results were not available. Patients who underwent haploidentical HCT were also excluded. Overall, 605 patients fulfilled these criteria, and thus were subjected to 1 subsequent analyses. Information was collected and compiled with regard to patient-related factors (that is, age and sex), disease-related factors (that is, cytogenetics, WBC count and dysplasia in morphology), number of induction courses, related donor availability, and clinical outcome. For patients who underwent allogeneic HCT, complementary information on HCT (that is, interval from CR1 to HCT, disease status at time of HCT, conditioning regimen and donor source) was also collected. Patients were considered to have a related donor if HLA typing identified a matched or one Ag-mismatched family donor. Unrelated donor selection was based on matching at the level of resolution available at the time of transplantation. This study was approved by the Institutional Review Board at the National Cancer Center Hospital.
Statistical analysis
Distributions of patient characteristics between groups were compared by using the w 2 test for categorical variables and the Wilcoxon rank-sum test for continuous variables. The probabilities of OS and relapse-free survival (RFS) were estimated by the Kaplan-Meier method, with differences between groups qualified by the log-rank test. Relapse and non-relapse mortality (NRM) were considered as competing risk events for each other. The probabilities of relapse and NRM were estimated by the cumulative incidence functions, and differences between groups were qualified by the Gray test. The Cox proportional hazards regression model was used for univariate and multivariate analyses, and a hazard ratio (HR) was calculated in conjunction with a 95% confidence interval (CI). All statistical analyses were performed with SPSS software version 11.0.1 (SPSS, Chicago, IL, USA) and R software version 2.13.0 (The R Foundation for Statistical Computing).
RESULTS

Patient characteristics
Of the 605 patients eligible for analysis, a related donor was found for 253 patients (42%) during CR1. There were no significant differences between the groups in the distribution of baseline characteristics, with the exception of WBC count (Table 1 ). Figure 1 shows the patient flow with respect to related donor availability, allogeneic HCT in CR1 and relapse. Among the 253 patients with a related donor, 157 (62%) underwent allogeneic HCT in CR1 (156 from a related donor and 1 from an unrelated BM donor). Of the 352 patients without a related donor, allogeneic HCT was performed during CR1 in 146 patients (41%), of whom 109 and 37 received unrelated BMT and umbilical cord blood (UCB) transplantation, respectively. In all, 96 patients with a related donor and 206 patients without a related donor did not receive allogeneic HCT during CR1. Among them, 25 (26%) and 49 (24%) patients experienced early relapse within 6 months after achievement of CR1. Autologous HCT was performed during CR1 in 5 and 14 patients with and without a related donor, respectively.
Characteristics of patients who underwent allogeneic HCT in CR1
The characteristics of patients who underwent allogeneic HCT in CR1 are summarized according to related donor availability in Table 2 . The two groups were well balanced in terms of baseline characteristics. However, patients without a related donor were more likely to receive two courses of induction therapy instead of one course (P ¼ 0.023). The interval from CR1 to transplantation differed significantly between the groups (Figure 2) , with a median interval of 3.7 months for patients with a related donor vs 5.9 months for patients without a related donor (Po0.001). Myeloablative conditioning was used in 89% and 88% of patients with and without a related donor, respectively.
Outcome after CR1 according to related donor availability The median follow-up of surviving patients was 4.4 years (range, 0.1-9.7), and the 4-year OS was 60% for the entire population. Figure 3 shows Kaplan-Meier survival estimates for patients with and without a related donor. The 4-year OS was 62% in patients with a related donor and 59% in patients without a related donor, with no significant difference detected (P ¼ 0.534). Similar results were obtained when the analysis was restricted to patients with unfavorable cytogenetic risk (51% vs 44% at 4 years, P ¼ 0.213) or those with intermediate cytogenetic risk (67% vs 67% at 4 years, P ¼ 0.744). In the multivariate analysis, cytogenetics and number of induction courses were identified as factors that were significantly associated with OS, whereas related donor availability had no significant impact (Table 3) . 
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Outcome after allogeneic HCT in CR1 according to related donor availability Figure 4 compares post-transplant OS between patients with and without a related donor who underwent allogeneic HCT during CR1. There was no difference in OS between the groups: the 4-year OS was 65% in patients with a related donor and 61% in patients without a related donor (P ¼ 0.262). The cumulative incidence of NRM in patients with a related donor was significantly lower than that in patients without a related donor (13% vs 21% at 4 years, P ¼ 0.022). In terms of relapse, patients with a related donor appeared to show a higher incidence, but the difference was not statistically significant (26% vs 21% at 4 years, P ¼ 0.292). OS with unrelated BMT was superior to that with UCB transplantation (66% vs 48% at 4 years, P ¼ 0.044): the former was equivalent to the result with related HCT (P ¼ 0.897), whereas the latter was worse (P ¼ 0.003). Related HCT from a matched (N ¼ 140) and one Ag-mismatched donor (N ¼ 16) showed no difference in OS (66% vs 56% at 4 years, P ¼ 0.304).
Effect of allogeneic HCT during CR1 in patients with or without a related donor To examine how allogeneic HCT in CR1 impacted RFS and OS, we performed separate multivariate analysis for patients with and without a related donor. In this analysis, HCT was considered as a time-dependent covariate, and adjustments were made for all of the variables listed in Table 3 (Figure 1 ). After relapse, 65 (88%) patients with a related donor received allogeneic HCT (62 from a related donor, 2 from an unrelated BM donor and 1 from UCB), as did 107 (75%) patients without a related donor (63 from an unrelated BM donor, 42 from UCB and 1 from a related donor who had not been included in the initial related donor search; information was missing for 1 patient). In all, 27 patients with a related donor and 44 patients without a related donor received allogeneic HCT during CR2. For patients who experienced relapse without having received allogeneic HCT in CR1, the 4-year OS after relapse was 33% in patients with a related donor and 33% in patients without a related donor (P ¼ 0.245).
DISCUSSION
The outcome of unrelated HCT has recently improved primarily due to the introduction of high-resolution HLA-typing technology and improvements in supportive care. In addition, the growth of unrelated donor registries as well as the increased use of UCB grafts has increased the chance of finding an unrelated donor. 1 These advances have made unrelated HCT a more feasible option for patients who lack a related donor. As our analyses were based on a nationwide multicenter survey, the finding that 41% of patients without a related donor received unrelated HCT during CR1 reflects the widespread use of unrelated HCT in Japan. On the other hand, in patients with a related donor, the proportion of patients who underwent allogeneic HCT during CR1 reached 62%. This value was comparable to or only slightly lower than the HCT compliance rates reported in previous donor vs no-donor studies, where allogeneic HCT was offered to all patients with a related donor as per the study protocol. [2] [3] [4] [5] [6] [7] [8] These findings show that allogeneic HCT, from both related and unrelated donors, was actively incorporated into the treatment strategy in our patient population.
When we take into account that patients with core-binding factor AML were excluded from our study, the 60% 4-year OS for the entire cohort appears quite favorable. Recently, the Japan Adult Leukemia Study Group reported results from a prospective study (designated AML201) for newly diagnosed AML patients, in which standard-dose and high-dose cytarabine (AraC)-based regimens were compared for post-remission therapy. 12 In that study, for patients younger than 50 years, the 5-year OS was 66% with standard-dose AraC consolidation and 62% with high-dose AraC consolidation. As the AML201 study included patients with core-binding factor AML (28% of the total population), and the patients in that study were selected according to the pre-defined inclusion and exclusion criteria, it is remarkable that a comparable survival rate was achieved in our patients. The active use of allogeneic HCT not only in patients with a related donor but also in those without a related donor likely contributed to the favorable overall outcome of our patients.
In contrast to the results of meta-analysis studies of the prospective donor vs no-donor comparison, [8] [9] [10] our patients with and without a related donor had comparable OS. Similar results were obtained if the outcome was compared in terms of RFS (data not shown). The most likely explanations for this result is that up to 41% of our patients without a related donor proceeded to unrelated HCT during CR1, and that OS after allogeneic HCT in CR1 did not differ between patients with and without a related donor. NRM is a major obstacle to the success of unrelated HCT. Early studies showed less satisfactory results with unrelated HCT because of a high incidence of NRM. 13, 14 However, according to more recent data, comparable outcomes have been reported for related and unrelated HCT in AML patients. [15] [16] [17] [18] In our study, the cumulative incidence of NRM in patients undergoing unrelated HCT was significantly higher than that in those undergoing related HCT (21% vs 13%, P ¼ 0.022), but the NRM rate of 21% with unrelated HCT appears to be within the acceptable range. The benefits of unrelated HCT may be increased by reducing NRM with the aid of stricter matching between donor and patient, increasing the use of reducedintensity conditioning, and applying better supportive care. Recently, several groups have conducted prospective donor vs no-donor studies for AML patients with high-risk features by expanding the type of donor to include unrelated donors. [19] [20] [21] Notably, despite a limited number of patients in each study, they showed significantly superior OS in patients with a donor, as well as comparable OS in patients undergoing related and unrelated HCT. [19] [20] [21] These prospective studies also support the usefulness of unrelated HCT in younger AML patients with non-favorable cytogenetics. Although our multivariate analysis showed that the degree to which allogeneic HCT had favorably affected outcome was less marked in patients without a related donor compared with those with a related donor, unrelated HCT could be considered a reasonable treatment option if a related donor is not available.
When our data are interpreted, it should be remembered that this study was an observational study, not an interventional study. The decision of whether or not to proceed to allogeneic HCT could be confounded by multiple factors, and early relapse, for example, did not seem to be a main cause for not having undergone allogeneic HCT during CR1 in our study. Adjusting for known confounding factors by using a multivariate analysis cannot guarantee that biases are removed. Thus, the results presented here need to be interpreted cautiously. Although we acknowledge such a limitation, our data showed that related donor availability did not significantly affect OS in younger patients with cytogenetically non-favorable AML. We consider this was because 41% of the patients without a related donor underwent unrelated HCT during CR1, and the outcome after transplantation was comparable between related and unrelated HCT. These results show the usefulness of unrelated HCT in this patient population when they do not have a related donor. The extensive use of unrelated HCT for such patients may minimize the potential disadvantage of lacking a related donor.
